U.S. Markets closed

Array BioPharma to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference

BOULDER, Colo., Feb. 21, 2019 /PRNewswire/ -- Array BioPharma Inc. (ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the SVB Leerink Partners 8th Annual Global Healthcare Conference in New York.  The public is welcome to participate in the conference through a webcast on the Array BioPharma website.   

Event:              SVB Leerink Partners 8th Annual Global Healthcare Conference
Presenter:       Ron Squarer, Chief Executive Officer, Array BioPharma
Date:                Thursday, February 28, 2019
Time:               10:00 a.m. Eastern Time
Webcast:         http://wsw.com/webcast/leerink32/arry/

A replay of the presentation will also be accessible under the "Investors/Investor Calendar" section of the website at www.arraybiopharma.com.

About Array BioPharma 
Array BioPharma Inc. is a fully-integrated, biopharmaceutical company focused on the discovery, development and commercialization of transformative and well-tolerated targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. Array markets BRAFTOVI® (encorafenib) capsules in combination with MEKTOVI® (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation in the United States and with partners in other major worldwide markets. Array's lead clinical programs, encorafenib and binimetinib, are being investigated in over 30 clinical trials across a number of solid tumor indications, including a Phase 3 trial in BRAF-mutant metastatic colorectal cancer. Array's pipeline includes several additional programs being advanced by Array or current license-holders, including the following programs currently in registration trials: selumetinib (partnered with AstraZeneca), LOXO-292 (partnered with Eli Lilly), ipatasertib (partnered with Genentech), tucatinib (partnered with Seattle Genetics) and ARRY-797. Vitrakvi® (larotrectinib, partnered with Bayer AG) is approved in the United States and Ganovo® (danoprevir, partnered with Roche) is approved in China. For more information on Array, please visit www.arraybiopharma.com or follow @arraybiopharma on Twitter and LinkedIn.

BRAFTOVI® and MEKTOVI® are registered trademarks of Array BioPharma Inc. in the United States and various other countries. Vitrakvi® is a registered trademark of Bayer AG. All trademarks are properties of their respective owners.

CONTACT:       
Andrea N. Flynn, Ph.D.
Senior Director, Investor Relations & Corporate Communications
(303) 381-6600
ir@arraybiopharma.com

 

Array BioPharma. (PRNewsFoto/Array BioPharma Inc.) (PRNewsFoto/)

 

Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/array-biopharma-to-present-at-the-8th-annual-svb-leerink-partners-global-healthcare-conference-300799914.html